

## Accepted Manuscript

Title: N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus

Authors: Janina Geiler, Martin Michaelis, Patrizia Naczk, Anke Leutz, Klaus Langer, Hans-Wilhelm Doerr, Jindrich Cinatl Jr.



PII: S0006-2952(09)00728-X  
DOI: doi:10.1016/j.bcp.2009.08.025  
Reference: BCP 10309

To appear in: *BCP*

Received date: 16-6-2009  
Revised date: 26-8-2009  
Accepted date: 27-8-2009

Please cite this article as: Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr H-W, Cinatl Jr. J, N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2009.08.025

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**N-acetyl-L-cysteine (NAC) inhibits virus replication and  
expression of pro-inflammatory molecules in A549 cells infected  
with highly pathogenic H5N1 influenza A virus**

Janina Geiler<sup>1</sup>, Martin Michaelis<sup>1</sup>, Patrizia Naczki<sup>1</sup>, Anke Leutz<sup>1</sup>, Klaus Langer<sup>2</sup>, Hans-  
Wilhelm Doerr<sup>1</sup> and Jindrich Cinatl jr.<sup>1\*</sup>

<sup>1</sup> Institute of Medical Virology, Johann Wolfgang Goethe-University Frankfurt, Paul-  
Ehrlich-Strasse 40, 60596 Frankfurt am Main

<sup>2</sup> Institute of Pharmaceutical Technology and Biopharmacy, WWU Münster, Correnstrasse  
1, 48149 Münster

\*Corresponding author Phone: (+49)696301-6409

Fax: (+49)696301-4302

E-mail: cinatl@em.uni-frankfurt.de

Short title: Inhibitory effect of NAC on influenza A H5N1 infection

**ABSTRACT**

1  
2  
3 The antioxidant N-acetyl-L-cysteine (NAC) had been shown to inhibit replication of  
4 seasonal human influenza A viruses. Here, the effects of NAC on virus replication, virus-  
5 induced pro-inflammatory responses and virus-induced apoptosis were investigated in  
6 H5N1-infected lung epithelial (A549) cells. NAC at concentrations ranging from 5 to 15  
7 mM reduced H5N1-induced cytopathogenic effects (CPE), virus-induced apoptosis and  
8 infectious viral yields 24 hours post-infection. NAC also decreased the production of pro-  
9 inflammatory molecules (CXCL8, CXCL10, CCL5, interleukin-6 (IL-6)) in H5N1-infected  
10 A549 cells and reduced monocyte migration towards supernatants of H5N1-infected A549  
11 cells. The antiviral and anti-inflammatory mechanisms of NAC included inhibition of  
12 activation of oxidant sensitive pathways including transcription factor NF- $\kappa$ B and mitogen  
13 activated protein kinase p38. Pharmacological inhibitors of NF- $\kappa$ B (BAY 11-7085) or p38  
14 (SB203580) exerted similar effects like those determined for NAC in H5N1-infected cells.  
15 The combination of BAY 11-7085 and SB203580 resulted in increased inhibitory effects  
16 on virus replication and production of pro-inflammatory molecules relative to either single  
17 treatment. NAC inhibits H5N1 replication and H5N1-induced production of pro-  
18 inflammatory molecules. Therefore, antioxidants like NAC represent a potential additional  
19 treatment option that could be considered in the case of an influenza A virus pandemic.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 **Keywords:** ROS, NAC, cytokines, H5N1, apoptosis  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 1. Introduction

1  
2  
3 Highly pathogenic H5N1 influenza A viruses are considered to be potential  
4 progenitors of a novel influenza pandemic [1-6]. Human infections with highly pathogenic  
5 influenza A H5N1 viruses are associated with severe pneumonia, lymphopenia, high viral  
6 loads in the respiratory tract, and hyper-induction of cytokines and chemokines (cytokine  
7 storm) [7]. Pathological investigations revealed that induction of apoptosis may be a major  
8 mechanism in the destruction of alveolar epithelial cells in humans infected with H5N1 [8].  
9 Apoptosis may be a direct consequence of virus replication as well as result from excessive  
10 inflammatory responses to virus infection [6].  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 Production of reactive oxygen species (ROS) has been shown to contribute to  
24 pulmonary damage caused by influenza virus infection [9-11]. Recently, ROS were  
25 suggested to contribute to acute lung injury in people with severe influenza A virus  
26 infection by triggering the signalling of oxidised phospholipids through toll-like receptor 4  
27 (TLR4)-TIR-domain-containing adaptor-inducing interferon- $\beta$  (TRIF)-TNF receptor  
28 associated factor 6 (TRAF6) cascade [12, 13]. Different sources of ROS have been  
29 suggested in influenza A virus-infected lungs. Leukocytes may be activated and primed by  
30 influenza A virus infection and produce ROS [14]. Moreover, increased xanthine oxidase  
31 levels were found in influenza A virus-infected lungs [14]. Epithelial cells of the lungs  
32 may also be a source of ROS since influenza A virus infection induced oxidant stress  
33 response in cultured airway epithelial [15, 16].  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 Endogenous oxidants may be involved in signal transduction pathways that  
52 stimulate production of cytokines/chemokines through activation of transcription factors  
53 and induction of pro-inflammatory gene expression in influenza A-infected cells [16].  
54 Influenza A viruses including H5N1 strains were shown to induce expression of cytokines  
55 and chemokines, including CXCL8 (also known as interleukin-8), interleukin-6 (IL-6),  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

CXCL10 (also known as interferon-inducible cytokine IP-10), and CCL5 (also known as RANTES) in macrophages and airway epithelial cells through oxidant sensitive pathways such as mitogen activated kinase p38 and the transcription factor nuclear factor- $\kappa$ B (NF- $\kappa$ B) [2, 17-19].

Antioxidant molecules including reduced glutathione and its precursor N-acetyl-L-cysteine (NAC) are potentially useful against infection with influenza A viruses [20-23]. Notably, NAC was already shown to synergise with oseltamivir in the treatment of lethal seasonal influenza A virus infection in a mouse model [23]. Here, we investigated the effects of NAC as prototype antioxidant on virus replication, virus-induced apoptosis, and expression of pro-inflammatory molecules in A549 cells infected with human H5N1 influenza A virus. Moreover, the influence of NAC on NF- $\kappa$ B and p38, both constituents of cellular signalling pathways known to be of relevance for influenza A virus replication, was studied in H5N1-infected cells.

## 2. Material and methods

### 2.1 Virus stock

The H5N1 Influenza A strain A/Thailand/1(Kan-1)/04 was obtained from Prof. Pilaipan Puthavathana (Mahidol University, Bangkok). The H5N1 Influenza A strain A/Vietnam/1203/04 was received from the WHO Influenza Centre at the National Institute for Medical Research London (Great Britain). Virus stock were prepared by infecting Vero cells (African green monkey kidney; ATCC: CCL81, Manassas, VA, USA) and aliquots were stored at -80°C. Virus titres were determined as 50% tissue culture infectious dose (TCID<sub>50</sub>/ml) in confluent cells in 96-well microtiter plates (Greiner Bio-One, Frickenhausen, Germany).

### 2.2 Cells

A549 cells (human lung carcinoma; ATCC: CCL-185, Manassas, VA, USA) and Vero cells were grown at 37°C in minimal essential medium (MEM, Biochrom AG, Berlin, Germany) supplemented with 10% foetal bovine serum (FBS, Sigma-Aldrich Chemie GmbH, Munich, Germany), 100 IU/ml penicillin (Grünethal GmbH, Aachen, Germany) and 100µg/ml streptomycin (Sigma-Aldrich Chemie GmbH, Munich, Germany).

### 2.3 Drugs

N-acetyl-L-cysteine (NAC) was obtained from Alexis (distributed by Axxora, Germany), dissolved in unsupplemented MEM and adjusted to pH 7.4 with NaOH. The caspase-3 inhibitor Ac-DEVD-CHO, the NF-κB inhibitor BAY 11-7085 and the p38 MAP kinase inhibitor SB 203580 were obtained from Merck Biosciences (Darmstadt, Germany).

#### 2.4 Cell viability assay

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Confluent A549 cells were treated with NAC for 48 h. The cellular viability was assessed with CellTiter-Glo<sup>®</sup> Luminescent Cell Viability Assay (Promega GmbH, Mannheim, Germany) according to the manufacturers' protocol. Cell viability was expressed as percentage of non-treated control.

#### 2.5 Cytopathogenic effect (CPE) reduction assay

Confluent A549 cell layers were infected with influenza A (H5N1) at an MOI of 0.01 in MEM supplemented with 2% FBS, 100 IU/ml penicillin and 100µg/ml streptomycin. Cells were continuously treated with NAC starting with a 24 h pre-incubation period prior to infection. 24 h post-infection (p.i.) the virus induced CPE was recorded using an inverted light microscope (Olympus, Planegg, Germany).

#### 2.6 Virus yield reduction assay

Confluent A549 cell layers were infected with influenza A (H5N1) at an MOI of 0.01 in MEM supplemented with 2% FBS, 100 IU/ml penicillin and 100µg/ml streptomycin. Cells were continuously treated with NAC starting with a 24 h pre-incubation period prior to infection. At the given time points, aliquots of the supernatants were taken and serial 10-fold dilution steps were performed. Infectivity was determined by endpoint dilution titration onto Vero cells in 96-well microtiter plates. Plates were incubated for 3 to 4 days and infectivity was analysed by virus-induced cytopathic effect. Virus titres were calculated by the method of Reed and Muench [24].

#### 2.7 Indirect immunofluorescence microscopy

Confluent A549 cell layers infected with influenza A (H5N1) at an MOI of 0.1 were treated with NAC (15 mM) or Caspase-3 Inhibitor I (20µM, non-toxic concentration, data

1 not shown). Cells were continuously treated with NAC or Ac-DEVD-CHO starting with a  
2 24 h or 1 h pre-incubation period, respectively, prior to infection. Eight hours p.i., cells  
3 were fixed for 15 min with ice-cold acetone/methanol (40:60, Mallinckrodt Baker B.V.,  
4 Deventer, The Netherlands) and stained with a mouse monoclonal antibody (1 h  
5 incubation, 1:1000 in PBS) directed against the influenza A virus nucleoprotein (NP)  
6 (Millipore, Molsheim, France). As secondary antibody an Alexa Fluor 488 goat anti-mouse  
7 IgG (H&L) (Invitrogen, Eugene, Oregon, USA) was used (1 h incubation, 1:1000 in PBS).  
8 Nuclei were stained using 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich Chemie  
9 GmbH, Munich, Germany). Fluorescence was visualised using Olympus IX 1 fluorescence  
10 microscope (Olympus, Planegg, Germany).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 *2.8 Isolation of human monocytes*

27 Human monocytes were isolated from buffy coats of healthy donors, obtained from  
28 Institute of Transfusion Medicine and Immune Haematology, German Red Cross Blood  
29 Donor Center, Johann Wolfgang Goethe-University, Frankfurt am Main. After  
30 centrifugation on Ficoll (Biocoll)-Hypaque density gradient (Biochrom AG, Berlin,  
31 Germany) mononuclear cells were collected from the interface and washed with PBS  
32 (Sigma-Aldrich Chemie GmbH, Munich, Germany). Then, monocytes were isolated using  
33 magnetically labeled CD14 MicroBeads (Miltenyi Biotec GmbH, Bergisch Gladbach,  
34 Germany) following the manufacturer's instructions. Monocytes were cultivated in IMDM  
35 supplemented with 10% pooled human serum, 100 IU/ml of penicillin, and 100µg/ml  
36 streptomycin.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

### 54 *2.9 Migration assay*

55 Cell culture supernatants were investigated for chemotactic activity by measurement of the  
56 activity to induce monocyte migration through membrane inserts in 24-well plates (pore  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 size 8µm; BD Biosciences, Heidelberg, Germany). Monocytes ( $1 \times 10^6$  in 100µl of IMDM  
2 with 10% pooled human serum) were added into the cell culture inserts (upper chamber)  
3 and cell culture supernatants (300µl) were added to the lower chamber of the well. After a  
4 48 h incubation period, cells were fixed with 4% paraformaldehyde and permeabilised with  
5 PBS containing 0.3% Triton X-100. Then, nuclei were stained with DAPI. The upper side  
6 of the membrane was wiped with a wet swab to remove the cells, while the lower side of  
7 the membrane was rinsed with PBS. The number of cells at the lower side of each  
8 membrane was quantified by counting of cells from three randomly chosen sections (3.7  
9 mm<sup>2</sup>) using a Olympus IX 1 fluorescence microscope.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

#### 24 *2.10 Cytokine/Chemokine secretion*

25 Cell culture supernatants were collected and frozen at -80°C. Cytokines/Chemokines were  
26 quantified by specific ELISA Duo Sets (R&D Systems GmbH, Wiesbaden, Germany)  
27 following the manufacturer's instructions.  
28  
29  
30  
31  
32  
33  
34  
35

#### 36 *2.11 NF-κB activity*

37 NF-κB activity was investigated by quantification of the NF-κB subunits Rel A (p65) and  
38 NF-κB1 (p50) from nuclear extracts using the NF-κB Transcription Factor assay kit  
39 (Active Motif, Rixensart, Belgium).  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

#### 50 *2.12 Western blot analysis*

51 Cells were lysed in Triton X-sample buffer and separated by SDS-PAGE. Proteins were  
52 detected using specific antibodies against β-actin (Sigma-Aldrich, Taufkirchen, Germany),  
53 p38 (anti- p38 MAP kinase Ab, New England Biolabs GmbH, Frankfurt am Main,  
54 Germany) or phosphorylated p38 (anti-phospho-specific p38 MAP kinase Ab, New  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 England Biolabs GmbH, Frankfurt am Main, Germany) and were visualised by enhanced  
2 chemiluminescence using a commercially available kit (Amersham, Freiburg, Germany).  
3  
4  
5  
6

### 7 *2.13 Caspase activity*

8  
9 Cells were tested for caspase activity (expressed as relative luminescence units (RLU))  
10 using the Caspase-Glo<sup>®</sup> 3/7, -8, and 9 Assay kit (Promega GmbH, Mannheim, Germany)  
11 following the manufacturer's instructions. Luminescence was measured using TECAN  
12 Infinite 200 (Tecan Deutschland GmbH, Crailsheim, Germany).  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 *2.14 Statistical analysis*

23 All data are given as the mean  $\pm$  SD. Statistical analysis was performed using Statistical  
24 analysis of results was performed by Student t test. *p* values of  $<0.05$  were considered  
25 statistically significant.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3. Results

#### 3.1 Influence of NAC on H5N1 virus replication in A549 cells

To investigate effects of NAC on influenza A H5N1 virus replication in A549 cells, confluent cell layers infected with A/Thailand/1(Kan-1)/04 (Kan-1) or A/Vietnam/1203/04 (VN1203) at an MOI of 0.01 were treated with NAC at concentrations ranging from 5 to 15 mM. Cells were continuously treated with NAC starting with a 24 h pre-incubation period prior to infection (if not stated otherwise cells were treated like this throughout all experiments described in this report). Supernatants were collected 12 h, 24 h, or 48 h post-infection (p.i.) and virus titres were determined as TCID<sub>50</sub>/ml. NAC reduced the titres of influenza A/Thailand/1(Kan-1)/04 in a concentration-dependent manner (Fig. 1A). Twelve hours post infection (p.i.), no significant decrease of virus titres was observed. Treatment with 10 mM NAC significantly decreased the Kan-1 virus titre about 5.6-fold (24 h p.i.) and about 2.1-fold (48 h p.i.) compared to mock-treated virus control. Treatment with 15 mM NAC reduced the titres about 34.5-fold (24 h p.i.) and 5.8-fold (48 h p.i.). Similar results were obtained with A/Vietnam/1203/04. Significant reduction of virus replication was observed after treatment with 15 mM NAC 12 h p.i. (2.2-fold reduction), 24 h p.i. (48.9-fold reduction) and 48 h p.i. (25.2-fold reduction) and after treatment with 10 mM and 5 mM NAC 48 h p.i. (7.1-fold and 2.2 fold reduction). In addition, treatment of H5N1 (Kan-1)-infected cells with NAC (15 mM) almost completely suppressed formation of cytopathogenic effects (CPE) (Fig. 1B). None of the tested NAC concentrations affected A549 cell viability (data not shown). Further experiments were performed with the influenza A strain A/Thailand/1(Kan-1)/04.

### 3.2 Influence of NAC on H5N1-induced caspase activation

1  
2  
3 ROS formation may result in caspase-dependent apoptosis and virus-induced apoptosis  
4  
5 may be a major mechanism in the destruction of epithelial cells infected with H5N1 both *in*  
6  
7 *vitro* and *in vivo* [8, 25]. To investigate the influence of NAC on H5N1-induced apoptosis  
8  
9 in A549 cells, cells were treated with or without NAC and infected with H5N1 at an MOI  
10  
11 of 0.01. 24 hours p.i., cells were analysed for caspase-8, -9 and -3/7 activity. H5N1  
12  
13 infection increased the caspase-8 (2.1-fold), caspase-9 (2.4-fold) and caspase-3/7 (7.7-fold)  
14  
15 activity relative to the mock infected cells (Fig. 2A, 2B and 2C). In H5N1-infected cells,  
16  
17 NAC reduced activities of all investigated caspases in a dose dependent manner. Compared  
18  
19 to virus control, NAC 15 mM treatment decreased caspase-8 activity by 1.6-fold, caspase-9  
20  
21 activity by 1.8-fold, and caspase-3/7 activity by 5.4-fold.  
22  
23  
24  
25  
26

27  
28 Moreover, inhibition of caspase 3 resulted in retention of influenza virus ribonucleoprotein  
29  
30 (RNP) complexes in the nucleus of infected cells and in turn to inhibition of influenza A  
31  
32 virus replication [26]. To investigate the influence of NAC on retention of RNP  
33  
34 complexes, A549 cells were treated with or without 15 mM NAC or caspase 3 inhibitor  
35  
36 and infected with H5N1 (MOI 0.1). Eight hours p.i., cells were analysed for RNP export.  
37  
38 Similar to the caspase 3 inhibitor that served as positive control, NAC inhibited nuclear  
39  
40 export of the viral RNP as indicated by immunofluorescence staining (Fig. 3).  
41  
42  
43  
44  
45  
46  
47

### 3.3 Influence of NAC on cytokine and chemokine production in H5N1-infected cells

48  
49  
50  
51 Virus-induced cytokine/chemokine storm seems to contribute to severe pathogenesis of  
52  
53 H5N1 infection in humans [6]. In addition to investigation of virus inhibitory effects, the  
54  
55 influence of NAC on the production of cytokines/chemokines which had been correlated to  
56  
57 progression of H5N1 disease was studied. Supernatants from mock- or H5N1-infected  
58  
59 cultures were compared for expression of CCL5, IL-8, CXCL10 and IL-6 by ELISA (Fig.  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

4). Mock-infected cells produced low levels of all cytokines/chemokines tested. Basic levels were  $53.6 \pm 8.6$  pg/ml for CCL5,  $627.8 \pm 119.7$  pg/ml for CXCL8,  $26.4 \pm 10.4$  pg/ml for CXCL10 and  $156.8 \pm 43.5$  pg/ml for IL-6. H5N1 infection increased production of CCL5 by 30.0-fold ( $1\ 607 \pm 240.4$  pg/ml), of CXCL8 by 2.9-fold ( $1\ 826 \pm 47.2$  pg/ml), of CXCL10 by 15.6-fold ( $412.1 \pm 85.7$  pg/ml), and of IL-6 by 6.3-fold ( $985.5 \pm 170$  pg/ml). NAC did not significantly influence basal cytokine/chemokine levels in the investigated concentrations up to 15 mM (data not shown). The H5N1 induced cytokine secretion was reduced by NAC in a dose dependent manner. Fifteen mM NAC could reduce the CXCL-10 and IL-6 secretion to levels of untreated cells (mock) whereas the production of CXCL-8 or CCL-5 was significantly decreased in comparison to untreated H5N1-infected cells (1.7-fold or 6.0-fold reduction, respectively) but clearly remained higher than the mock levels (Fig. 4).

#### 3.4 Influence of NAC on chemoattraction of monocytes by supernatants from H5N1-infected A549 cells

H5N1 infection is characterised by massive infiltration of monocytes/macrophages into the lungs in humans [6]. The potential to attract immune cells including monocytes is a criterion for pro-inflammatory potential of (virus-infected) cells. Migration assays using supernatants from NAC-treated or –untreated uninfected or H5N1-infected (MOI 0.01) A549 cells to attract monocytes were performed. The number of migrated monocytes was 5 times higher towards supernatants of H5N1-infected cells than towards supernatants of uninfected cells (Fig. 5). NAC 15 mM treatment reduced monocyte migration towards supernatants of infected cells (3.1-fold decrease relative to virus control) (Fig. 5) but did not significantly affect migration of monocytes towards supernatants of mock-infected cells (data not shown).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3.5 Influence of NAC on activation of redox sensitive cellular signalling pathways relevant in influenza pathology

NF- $\kappa$ B and p38 are commonly activated in response to oxidative stress and known to be of relevance for influenza A virus replication and pathology [27-29]. NAC was shown to inhibit both H5N1-induced p38 and NF- $\kappa$ B activation (Fig. 6). NAC 15 mM inhibited H5N1-induced p38 phosphorylation as indicated by Western blot (Fig. 6A). Detection of induction of the NF- $\kappa$ B subunits Rel A (p65) and NF- $\kappa$ B1 (p50) in A549 nuclear cell extracts using a subunit specific NF- $\kappa$ B binding ELISA kit revealed that NAC inhibited H5N1-induced NF- $\kappa$ B activation (Fig. 6B). In untreated H5N1-infected A549 cells nuclear levels of p65 and p50 resulted in relative luminescence units (RLU) of  $3.8 \times 10^6 \pm 1.1 \times 10^5$  RLU and  $6.7 \times 10^6 \pm 1.9 \times 10^5$  RLU, respectively. In NAC 15 mM-treated H5N1-infected cells nuclear levels of p65 and p50 correlated to  $2.4 \times 10^6 \pm 1.6 \times 10^5$  RLU and  $4.1 \times 10^6 \pm 4.4 \times 10^5$  RLU, respectively.

### 3.6 Influence of specific pharmacological inhibitors of p38 or NF- $\kappa$ B on H5N1 replication in A549 cells

To test whether the antiviral activity of NAC may be mediated by inhibition of p38 and/or NF- $\kappa$ B activation, cells were treated with non-toxic concentrations of the p38 inhibitor SB203580 (20  $\mu$ M) and/or the NF- $\kappa$ B inhibitor BAY 11-7085 (20  $\mu$ M). Both inhibitors significantly reduced viral titres (SB203580: 15.2-fold decrease relative to virus control; BAY 11-7085: 2.4-fold decrease relative to virus control) (Fig. 7A). The combination of SB203580 and BAY 11-7085 resulted in a further (non-significant, compared to SB203580 treatment) decrease of viral titres (33.2-fold decrease relative to virus control).

3.7 Influence of specific pharmacological inhibitors of p38 or NF- $\kappa$ B on H5N1-induced expression of pro-inflammatory genes in A549 cells

To investigate whether NAC-mediated inhibition of cytokines/chemokines may be mediated by inhibition of p38 and/or NF- $\kappa$ B activation, cells were treated with the p38 inhibitor SB203580 (20  $\mu$ M) and/or the NF- $\kappa$ B inhibitor BAY 11-7085 (20  $\mu$ M) and pro-inflammatory cytokines/chemokines were measured by ELISA. Both inhibitors significantly reduced expression of CCL5 (untreated control:  $412.6 \pm 10.0$  pg/ml; SB203580:  $125.5 \pm 6.3$  pg/ml; BAY 11-7085:  $246.5 \pm 4.4$  pg/ml), CXCL8 (untreated control:  $989.2 \pm 14.8$  pg/ml; SB203580:  $417.1 \pm 12.4$  pg/ml; BAY 11-7085:  $839.0 \pm 10.7$  pg/ml), CXCL10 (untreated control:  $135.9 \pm 12.0$  pg/ml; SB203580:  $37.2 \pm 3.4$  pg/ml; BAY 11-7085:  $51.7 \pm 3.6$  pg/ml) and IL-6 (untreated control:  $263.6 \pm 33.5$  pg/ml; SB203580:  $13.9 \pm 9.3$  pg/ml; BAY 11-7085:  $115.5 \pm 19.8$  pg/ml) (Fig. 7B). The combination of SB203580 and BAY 11-7085 resulted in a further significant decrease of cytokine/chemokine expression (CCL5  $52.5 \pm 16.3$  pg/ml; CXCL8:  $309.4 \pm 26.2$  pg/ml; CXCL10:  $19.4 \pm 3.5$  pg/ml; IL-6: concentration below detection limit).

#### 4. Discussion

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

In the present paper, we demonstrate that NAC treatment inhibited H5N1 influenza A virus replication and H5N1-induced cell death. Moreover, NAC diminished H5N1-induced expression of the cytokines/chemokines CCL5, CXCL8, CXCL10 and IL-6 and migration of monocytes towards supernatants of H5N1-infected cells. NAC is an effective antioxidant. It enriches the intracellular sulfhydryl pool, acting as a precursor of reduced glutathione (GSH) [20]. Protective activity of NAC against seasonal influenza A infection was shown in animal studies by decreasing mortality of mice infected with the influenza A strain A/PR/8 (H1N1) [30]. In humans, NAC significantly reduced the incidence of clinically apparent A/H1N1 disease [20]. In cell culture experiments NAC prevented influenza A (H3N2) virus-induced oxidative stress, cell death, expression of inflammatory genes and NF- $\kappa$ B activity [16, 31].

It is probable that NAC antiviral activity against H5N1 virus results from its ability to inhibit activation of intracellular signalling molecules and transcription factors which are sensitive to oxidants produced during influenza A infection. In concordance, NAC treatment reduced formation of ROS in H5N1-infected cells [Figure S1, available as Supplementary data] as well as prevented activation of two constituents of redox-sensitive signalling pathways: 1) transcription factor NF- $\kappa$ B and 2) MAPK p38. Both signalling pathways are known to be involved in influenza A virus pathogenesis [28, 29, 32]. Numerous substances that cause inhibition of NF- $\kappa$ B including the radical scavenger pyrrolidine dithiocarbamate (PDTC), the proteasome inhibitor MG132, the cyclooxygenase (COX) inhibitor acetylsalicylic acid and the specific NF- $\kappa$ B inhibitor BAY11-7085 were shown to inhibit influenza A virus replication [33-35]. Similar to other NF- $\kappa$ B inhibitors, NAC concentrations required to block viral replication directly correlated with the



1 concentration needed to inhibit NF- $\kappa$ B. Moreover, the NF- $\kappa$ B inhibitor BAY11-7085 was  
2 also able to inhibit H5N1 replication in our setting.  
3

4  
5 NF- $\kappa$ B activation may result in inhibition or promotion of apoptosis depending on  
6 the cell type and the context [36]. NAC had already been shown to increase apoptosis in  
7 hypoxic cells through inhibition of NF- $\kappa$ B [37]. However, NAC had previously also been  
8 demonstrated to concomitantly impair influenza A (H3N2) virus-induced NF- $\kappa$ B activity  
9 and cell death [16]. Moreover, recent results demonstrated that different NF- $\kappa$ B inhibitors  
10 suppress apoptosis in H5N1-infected A549 cells [33]. Therefore, inhibition of H5N1  
11 replication as well as inhibition of H5N1-induced apoptosis by NAC in A549 cells may  
12 depend on its ability to interfere with virus-induced NF- $\kappa$ B activation. The two major  
13 apoptosis signalling pathways are death receptor-induced (extrinsic) apoptosis in which  
14 caspase 8 functions as initiator caspase and mitochondrial (intrinsic) apoptosis with  
15 caspase 9 as initiator caspase [38]. In our experiments, activation of both initiator caspases  
16 8 and 9 was observed after H5N1 infection suggesting that both apoptosis pathways may  
17 be involved in H5N1-induced apoptosis. Since NAC inhibited activation of both initiator  
18 caspases it may interfere with both apoptosis pathways. Moreover, inhibition of caspase 3  
19 activity by NAC may be directly relevant for its antiviral effects. Previous studies  
20 demonstrated that inhibition of caspase 3 in H5N1 infected A549 cells by acetylsalicylic  
21 acid resulted in efficient retention of influenza RNP complexes in the nuclei of infected  
22 A549 cells and in turn in inhibition of virus replication [33]. In concordance, suppression  
23 of caspase 3 activity by NAC was associated with increased retention of RNP in the nuclei  
24 of H5N1-infected A549 cells and concomitant inhibition of virus production.  
25  
26

27  
28 In addition to effects on NF- $\kappa$ B, NAC could influence virus replication by its  
29 interference with p38. Influenza A virus infection of different cell types may result in the  
30 activation of several MAPKs including p38. Our results also demonstrate that H5N1  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 infection activates p38 in A549 cells. p38 inhibition did not influence virus replication in  
2 macrophages or chorion cells cells infected with H1N1 or H5N1 virus strains in some  
3  
4 previous reports [28, 34, 39, 40]. In MDCK cells, however, the pharmacological p38  
5  
6 inhibitor SB203580 was shown to inhibit RNP transport from the nucleus to the cytosol  
7  
8 [32]. Since nuclear export of the RNP complex has been shown to be a critical step in  
9  
10 influenza A virus replication this suggests that p38 inhibition may affect H5N1 replication  
11  
12 in certain cell types [33]. In our model, the p38 inhibitor SB203580 inhibited H5N1  
13  
14 replication indicating that p38 activation may play a role for H5N1 replication in epithelial  
15  
16 cells. The combination of the NF- $\kappa$ B inhibitor BAY11-7085 and the p38 inhibitor  
17  
18 SB203580 caused increased inhibition of H5N1 replication compared to either single  
19  
20 treatment. Although differences did not achieve statistical significance this further supports  
21  
22 that NAC-induced inhibition of both pathways may contribute to the anti-H5N1 effects  
23  
24 exerted by NAC. Notably, NAC had been reported to impair RANTES expression without  
25  
26 affecting p38 phosphorylation in H1N1-infected bronchial epithelial cells (cell line NCI-  
27  
28 H292) [31]. These varying findings further stress that drug effects may depend on the  
29  
30 context and differ between different cells as well as between different viruses.  
31  
32  
33  
34  
35  
36  
37  
38

39 The mechanism of NAC-induced suppression of chemokine/cytokine production in  
40  
41 H5N1-infected cells appears to also involve inhibition of activation of p38 and NF- $\kappa$ B. The  
42  
43 p38 inhibitor SB203580 as well as the NF- $\kappa$ B inhibitor BAY 11-7085 both reduced  
44  
45 production of pro-inflammatory cytokines/chemokines in H5N1-infected cells.  
46  
47 Combination of both substances resulted in a significantly increased suppression of  
48  
49 production of pro-inflammatory molecules. Notably, NAC also inhibited H5N1-induced  
50  
51 caspase 3 activation [Figure S2, available as Supplementary data] and expression of pro-  
52  
53 inflammatory molecules [Figure S3, available as Supplementary data] in human monocyte-  
54  
55 derived macrophages indicating that anti-H5N1 effects of NAC may not be limited to  
56  
57 epithelial cells.  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Both pathways have already been suggested to be involved in H5N1-induced pro-inflammatory signalling. In human primary macrophages, H5N1 and H1N1 viruses did not differ in the activation of NF- $\kappa$ B but unlike H1N1 virus, H5N1 viruses strongly activated p38 resulting in production of inflammatory cytokines and chemokines [28, 39]. Similarly to these experiments with human macrophages, the treatment of A549 cells with SB203580 specific p38 inhibitor described here significantly suppressed expression of inflammatory cytokines/chemokines. In a transgenic mouse model with a deletion of p50 NF- $\kappa$ B subunit, H5N1 virus infection resulted in a lack of hypercytokinemia [41]. However, H5N1 pathogenesis was not altered in this model [41]. Moreover, cytokine and chemokine knockout mice or steroid-treated wild-type mice did not have survival advantage over wild-type mice after viral challenge [42]. These data indicate that suppression of cytokine/chemokine expression alone is not sufficient to improve disease outcome. However, control of excessive inflammation may have beneficial effects in combination with antiviral treatment that reduces virus loads. Indeed, delayed antiviral treatment with neuraminidase inhibitors in combination with immunomodulatory substances reduced mortality in mice infected by high inoculums of H5N1 virus [43]. In these experiments, significant improvements in survival rate, survival time, and inflammatory markers were reported for mice treated with a triple therapy containing zanamivir and immunomodulators including celecoxib, and mesalazine in comparison to zanamivir alone. Zanamivir with or without immunomodulators reduced viral load to a similar extent [43]. Therefore, antioxidants like NAC may serve as additional therapeutic options affecting in parallel H5N1 replication as well as H5N1-induced expression of pro-inflammatory molecules. Although NAC concentrations which showed antiviral and anti-inflammatory effects in H5N1 infected cells are unlikely to be achieved in humans by oral administration, NAC administered by alternative routes (inhalation, parental) may result in therapeutically effective concentrations.

**Acknowledgements**

1  
2 The work was supported by the EU grants SARS/FLU vaccine (proposal no. 512054),  
3  
4 Chimeric Vaccines (proposal no. 512864) and Intranasal H5 vaccine (proposal no.  
5  
6 044512), by the Hilfe für krebskranke Kinder Frankfurt e.V. and by the Frankfurter  
7  
8 Stiftung für krebskranke Kinder.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Accepted Manuscript

**References**

- 1  
2  
3 [1] Cinatl J Jr, Michaelis M, Doerr HW. The threat of avian influenza A (H5N1). Part I:  
4  
5 Epidemiologic concerns and virulence determinants. *Med Microbiol Immunol* 2007;  
6  
7 196:181-90.  
8  
9
- 10 [2] Cinatl J Jr, Michaelis M, Doerr HW. The threat of avian influenza A (H5N1): Part II:  
11  
12 Clues to pathogenicity and pathology. *Med Microbiol Immunol* 2007; 196:191-201.  
13  
14
- 15 [3] Cinatl J Jr, Michaelis M, Doerr HW. The threat of avian influenza A (H5N1). Part III:  
16  
17 Antiviral therapy. *Med Microbiol Immunol* 2007; 196:203-12.  
18  
19
- 20 [4] Cinatl J Jr, Michaelis M, Doerr HW. The threat of avian influenza A (H5N1). Part IV:  
21  
22 Development of vaccines. *Med Microbiol Immunol* 2007; 196:213-25.  
23  
24
- 25 [5] Maines TR, Szretter KJ, Perrone L, Belser JA, Bright RA, Zeng H, et al. Pathogenesis  
26  
27 of emerging avian influenza viruses in mammals and the host innate immune response.  
28  
29 *Immunol Rev* 2008; 225:68-84.  
30  
31
- 32 [6] Michaelis M, Doerr HW, Cinatl J Jr. Of chickens and men: avian influenza in humans.  
33  
34 *Curr Mol Med* 2009; 9:131-51.  
35  
36
- 37 [7] de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal  
38  
39 outcome of human influenza A (H5N1) is associated with high viral load and  
40  
41 hypercytokinemia. *Nat Med* 2006; 12:1203-7.  
42  
43  
44
- 45 [8] Uiprasertkul M, Kitphati R, Puthavathana P, Kriwong R, Kongchanagul A, Ungchusak  
46  
47 K, et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. *Emerg*  
48  
49 *Infect Dis* 2007; 13:708-12.  
50  
51
- 52 [9] Oda T, Akaike T, Hamamoto T, Suzuki F, Hirano T, Maeda H. Oxygen radicals in  
53  
54 influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD.  
55  
56 *Science* 1989; 244:974-6.  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [10] Han SN, Meydani S. Antioxidants, cytokines, and influenza infection in aged mice and elderly humans. *J Infect Dis* 2000; 182 Suppl 1:S74-80.
- [11] Akaike T. Role of free radicals in viral pathogenesis and mutation. *Rev Med Virol* 2001; 11:87-101.
- [12] Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. *Cell* 2008; 133:235-49.
- [13] Martin TR, Wurfel MM. A TRIFfic perspective on acute lung injury. *Cell* 2008 133:208-10.
- [14] Akaike T, Ando M, Oda T, Doi T, Ijiri S, Araki S, et al. Dependence on O<sub>2</sub>-generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. *J. Clin. Invest* 1990; 85:739-45.
- [15] Jacoby DB, Choi AM. Influenza virus induces expression of antioxidant genes in human epithelial cells. *Free Radic Biol Med* 1994; 16:821-4.
- [16] Knobil K, Choi AM, Weigand GW, Jacoby DB. Role of oxidants in influenza virus-induced gene expression. *Am J Physiol* 1998; 274:134-42.
- [17] Cheung CY, Poon LL, Lau AS, Shortridge KF, Gordon S, Guan Y, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? *Lancet* 2002; 360:1801-2.
- [18] Chan MC, Cheun CY, Chui WH, Tsao SW, Nicholls JM, Chan YO, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. *Respir Res* 2005; 6:135.
- [19] Kunsch C, Lang RK, Rosen CA, Shannon MF. Synergistic transcriptional activation of the IL-8 gene by NF- $\kappa$ B p65 (Rel A) and NF-IL-6. *J Immunol* 1994; 153:153-64.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [20] De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. *Eur Respir J* 1997; 10:1535-41.
- [21] Cai J, Chen Y, Seth S, Furukawa S, Compans RW, Jones DP. Inhibition of influenza infection by glutathione. *Free Radic Biol Med* 2003; 34:928-36.
- [22] Ghezzi P, Ungheri D. Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. *Int J Immunopathol Pharmacol* 2004; 17:99-102.
- [23] Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. *Int J Immunopathol Pharmacol* 2007; 20:349-54.
- [24] Reed LI, Muench H. A simple method of estimating fifty per cent endpoints. *Am J Hyg* 1938; 27:493-7.
- [25] Ryter SW, Kim HP, Hoetzel A, Park JW, Nakahira K, Wang X, et al. Mechanisms of cell death in oxidative stress. *Antioxid Redox Signal* 2007; 9:49-89.
- [26] Wurzer WJ, Planz O, Ehrhardt C, Giner M, Silberzahn T, Pleschka S, et al. Caspase 3 activation is essential for efficient Influenza virus propagation. *The EMBO Journal* 2003; 22:2717-28.
- [27] Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. *Eur Respir J* 2006; 28:219-42.
- [28] Lee DC, Cheung CY, Law AH, Mok CK, Peiris M, Lau AS. p38 mitogen-activated protein kinase-dependent hyperinduction of tumor necrosis factor alpha expression in response to avian influenza virus H5N1. *J Virol* 2005; 79:10147-54.
- [29] Ludwig S, Planz O. Influenza viruses and the NF-kappaB signaling pathway - towards

a novel concept of antiviral therapy. *Biol Chem* 2008; 389:1307-12.

[30] Ungheri D, Pisani C, Sanson G, Bertani A, Schioppacassi G, Delgado R, et al. Protective effect of n-acetylcysteine in a model of influenza infection in mice. *Int J Immunopathol Pharmacol* 2000; 13:123-8.

[31] Kujime K, Hashimoto S, Gon Y, Shimizu K, Horie T. p38 mitogen-activated protein kinase and c-jun-NH2-terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells. *J Immunol* 2000; 164:3222-8.

[32] Nencioni L, De Chiara G, Sgarbanti R, Amatore D, Aquilano K, Marcocci ME, et al. BCL-2 expression and p38MAPK activity in cells infected with influenza a virus: Impact on virally induced apoptosis and viral replication. *J Biol Chem* 2009; 284:16004-15.

[33] Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. *Cell Microbiol* 2007; 9:1683-94.

[34] Uchida N, Ohyama K, Bessho T, Toyoda H. Effects of mitogen-activated protein kinase inhibitors on tumor necrosis factor-alpha gene expression and apoptosis induction in cultured human fetal membrane chorion cells infected with influenza virus. *Intervirology* 2007; 50:99-107.

[35] Khor R, McElroy LJ, Whittaker GR. The ubiquitin-vacuolar protein sorting system is selectively required during entry of influenza virus into host cells. *Traffic* 2003; 4:857-68.

[36] Radhakrishnan SK, Kamalakaran S. Pro-apoptotic role of NF-kappaB: implications for cancer therapy. *Biochim Biophys Acta* 2006; 1766:53-62.

[37] Qanungo S, Wang M, Nieminen AL. N-Acetyl-L-cysteine enhances apoptosis through inhibition of nuclear factor-kappaB in hypoxic murine embryonic fibroblasts. *J Biol Chem* 2004; 279:50455-64.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [38] Danial NN, Korsmeyer SJ. Cell death: critical control points. *Cell* 2004; 116:205-19.
- [39] Hui KP, Lee SM, Cheung CY, Ng IH, Poon LL, Guan Y, et al. Induction of proinflammatory cytokines in primary human macrophages by influenza A virus (H5N1) is selectively regulated by IFN regulatory factor 3 and p38 MAPK. *J Immunol* 2009; 182:1088-98.
- [40] Mok CK, Lee DC, Cheung CY, Peiris M, Lau AS. Differential onset of apoptosis in influenza A virus H5N1- and H1N1-infected human blood macrophages. *J Gen Virol* 2007; 88:1275-80.
- [41] Droebner K, Reiling SJ, Planz O. Role of hypercytokinemia in NF-kappaB p50-deficient mice after H5N1 influenza A virus infection. *J Virol* 2008; 82:11461-6.
- [42] Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. *Proc Natl Acad Sci U S A* 2007; 104:12479-81.
- [43] Zheng BJ, Chan KW, Lin Y P, Zhao GY, Chan C, Zhang HJ, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. *Proc Natl Acad Sci U S A* 2008; 105:8091-6.

**Figure captions**

1  
2  
3  
4  
5 **Figure 1.** Influence of N-acetyl-L-cysteine (NAC) on H5N1 virus replication and  
6 cytopathogenic effect (CPE) formation in A549 cells. (a) A549 cells were infected with  
7 A/Thailand/1(Kan-1)/04 (Kan-1) or A/Vietnam/1203/04 (VN1203) at an MOI of 0.01.  
8 NAC treatment (0 mM NAC: dark grey bars, 5 mM NAC: middle grey bars, 10 mM NAC:  
9 light grey bars, 15 mM NAC: white bars) was performed continuously starting 24 hours  
10 prior to infection. H5N1 titres were determined 12 h, 24 h and 48 h post infection. Data  
11 represent the mean  $\pm$  SD of 3 independent experiments. (b) H5N1-induced formation of  
12 CPE in A549 cells at 24 h post infection. Representative photographs show non-infected  
13 cells (mock), cells infected with H5N1 strain A/Thailand/1(Kan-1)/04 at an MOI of 0.01,  
14 or H5N1-infected cells continuously treated with NAC 15 mM starting 24 hours prior to  
15 infection. \* =  $P < 0.05$  relative to untreated virus control.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32  
33  
34 **Figure 2.** Influence of N-acetyl-L-cysteine (NAC) treatment on caspase activation in  
35 H5N1-infected A549 cells. A549 cells were infected with A/Thailand/1(Kan-1)/04 (H5N1)  
36 at an MOI of 0.01. NAC treatment was performed continuously starting 24 hours prior to  
37 infection. 24h post infection cells were analysed for (a) caspase 8- (b) caspase 9- and (c)  
38 caspase 3/7-activity (expressed as relative luminescence units (RLU)) using Caspase-Glo<sup>®</sup>  
39 Assay kit. Data represent the mean  $\pm$  SD of 3 separate experiments. \* =  $P < 0.05$  relative to  
40 untreated virus control.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52  
53 **Figure 3.** Influence of N-acetyl-L-cysteine (NAC) treatment on nuclear export of viral NP  
54 in H5N1-infected A549 cells. A549 cells were infected with A/Thailand/1(Kan-1)/04  
55 (H5N1) at an MOI of 0.1. NAC 15 mM treatment was performed continuously starting 24  
56 hours prior to infection. Eight hours post infection NP localisation was visualised using  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

specific antibodies by immunofluorescence. NP staining is shown in green. Nuclei are stained by DAPI (shown in blue). Since caspase 3 inhibition is known to block nuclear export of NP in influenza A virus-infected cells, the Caspase-3 inhibitor Ac-DEVD-CHO (20 $\mu$ M, continuously treatment starting 1 hours prior infection) was used as positive control. Photographs are taken from one representative experiment. In total, three independent experiments were performed with similar results.

**Figure 4.** Influence of N-acetyl-L-cysteine (NAC) treatment on production of cytokines/chemokines in H5N1 infected A549. A549 cells were infected with A/Thailand/1(Kan-1)/04 (H5N1) at an MOI of 0.01. NAC treatment was performed continuously starting 24 hours prior to infection. 24h post infection supernatants were analysed for CCL5, CXCL8, CXCL10, or IL-6 using ELISA. Data represent the mean  $\pm$  SD of 3 separate experiments. \* =  $P < 0.05$  relative to untreated virus control.

**Figure 5.** Influence of N-acetyl-L-cysteine (NAC) treatment on H5N1-induced chemoattraction of monocytes. Motility assays using supernatants (24 h p.i.) from NAC-treated (15 mM, continuously treated starting 24 h prior to infection) or untreated MOCK- or H5N1- (strain A/Thailand/1(Kan-1)/04; MOI 0.01) infected A549 cells were performed. (a) Representative photographs show monocytes that migrated through 8  $\mu$ M-filters towards cell culture supernatants. (b) The number of migrated monocytes was determined as fold change relative to untreated mock. Data represent the mean  $\pm$  SD of 3 separate experiments. \* =  $P < 0.05$  relative to untreated virus control.

**Figure 6.** Influence of N-acetyl-L-cysteine (NAC) on p38 or nuclear factor  $\kappa$ B (NF- $\kappa$ B) signalling in H5N1-infected A549 cells. (a) Representative Western blot showing the influence of NAC (15 mM) on the levels of p38 and phosphorylated p38 (p-p38) in H5N1

1 strain A/Thailand/1(Kan-1)/04-infected A549 cells (MOI 0.01) 24 h post infection. NAC  
2 treatment was performed continuously starting 24 hours prior to infection.  $\beta$ -actin was used  
3 as loading control. (b) Effect of NAC on the H5N1-induced induction of the NF- $\kappa$ B  
4 subunits Rel A (p65) and NF- $\kappa$ B1 (p50) in A549 nuclear cell extracts using a subunit  
5 specific NF- $\kappa$ B binding ELISA kit 24 h post infection. NAC treatment was performed  
6 continuously starting 24 hours prior to infection. Data represent the mean  $\pm$  SD of 2  
7 separate experiments. \* = P < 0.05 relative to untreated virus control.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **Figure 7.** Influence of specific inhibitors of p38 (SB203580) or NF- $\kappa$ B (BAY 11-7085) on  
20 H5N1 replication and cytokine/chemokine expression in H5N1-infected A549 cells. A549  
21 cells were infected with A/Thailand/1(Kan-1)/04 (H5N1) at an MOI of 0.01. Treatment  
22 with SB203580 (20  $\mu$ M) and/or BAY 11-7085 (20  $\mu$ M) was performed continuously  
23 starting 1 hour prior to infection. (a) H5N1 titres were determined 24 h post infection. (b)  
24 Expression of CCL5, CXCL8, CXCL10 or IL-6 was determined 24 h post infection using  
25 ELISA. Data represent the mean  $\pm$  SD of 3 separate experiments. \* = P < 0.05 relative to  
26 untreated virus control. # = P < 0.05 relative to SB203580 or BAY 11-7085 treated virus  
27 infected cells.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Figure 1






Figure 2



crip



crip







Figure 4



CRIP

Figure 5






Figure 6

A



B



## SUPPLEMENTARY DATA

### Material and methods

#### *Examination of intracellular ROS in A549 cells*

ROS levels were analysed using Image-iT™ Live Green Reactive Oxygen Species Detection Kit (Invitrogen GmbH, Karlsruhe, Germany) according to the manufacturers' protocol. H5N1 or MOCK infected A549 cells pre-treated with or without 15mM NAC were rinsed three times with PBS and incubated with PBS containing 25µM carboxy-H<sub>2</sub>DCFDA at 37°C for 30min. After washing with PBS, cells were analysed using fluorescence microscope.


#### *Cytokine/Chemokine secretion and Caspase activity in monocytes-derived macrophages*

Monocytes were isolated as described in material and methods (2.8 *Isolation of human monocytes*). For differentiation, cell culture medium (10% pooled human serum, 100 IU/ml of penicillin and 100µg/ml streptomycin) was supplemented with 500 IU/ml recombinant human GM-CSF from PeproTech (distributed by Cell Concepts GmbH, Umkirch, Germany). Every second day a medium change was performed. After 14 days monocytes derived macrophages were infected with A/Thailand/1(Kan-1)/04 at an MOI of 2 and treated with NAC at concentrations ranging from 5 to 15 mM. Cells were continuously treated with NAC starting with a 24 h pre-incubation period prior to infection. 24 hours post-infection (p.i.) supernatants were collected and analysed for cytokine/chemokine expression as described in material and methods (2.10 *Cytokine/Chemokine secretion*) and cells were tested for caspase 3/7 activity as described in material and methods (2.13 *Caspase activity*).

**Figure S1.** Influence of N-acetyl-L-cysteine (NAC) treatment on ROS production in H5N1 infected A549 cells. Non-treated (MOCK), non-treated H5N1-infected (H5N1) and NAC-treated H5N1-infected (H5N1+NAC) cells are shown. NAC treatment was performed continuously starting 24 hours prior to infection with H5N1 strain A/Thailand/1(Kan-1)/04 (MOI 0.01). ROS was determined using carboxy-H2DCFDA (indicated in green) 24 h post infection. Nuclei were stained by DAPI (indicated in blue). Photographs are taken from one representative experiment. In total, three independent experiments were performed with similar results.

**Figure S2.** Influence of N-acetyl-L-cysteine (NAC) treatment on caspase activation in H5N1-infected monocytes-derived macrophages (MDM). MDM were infected with A/Thailand/1(Kan-1)/04 (H5N1) at an MOI of 2. NAC treatment was performed continuously starting 24 hours prior to infection.. 24h post infection cells were analysed for caspase 3/7-activity (expressed as relative luminescence units (RLU)) using Caspase-Glo<sup>®</sup> Assay kit. Data represent the mean  $\pm$  SD of 3 separate experiments. \* =  $P < 0.05$  relative to untreated virus control.

**Figure S3.** Influence of N-acetyl-L-cysteine (NAC) treatment on production of cytokines/chemokines in H5N1 infected monocytes-derived macrophages (MDM). MDM were infected with A/Thailand/1(Kan-1)/04 (H5N1) at an MOI of 2. NAC treatment was performed continuously starting 24 hours prior to infection. 24h post infection supernatants were analysed for CXCL10, CCL5, or IL-6 using ELISA. Data represent the mean  $\pm$  SD of 3 separate experiments. \* =  $P < 0.05$  relative to untreated virus control.

**Figure S1**



**Figure S2**

Figure S3





## The antioxidant N-acetyl-L-cysteine inhibits expression of pro-inflammatory cytokines in A549 cells infected with highly pathogenic H5N1 influenza virus

